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In this report, we reinvestigate the only patient ever reported with a deficiency of peroxisomal 3-ketoacyl-CoA
thiolase (THIO). At the time when they were described, the abnormalities in this patient, which included accu-
mulation of very-long-chain fatty acids and the bile-acid intermediate trihydroxycholestanoic acid, were believed
to be the logical consequence of a deficiency of the peroxisomal b-oxidation enzyme THIO. In light of the current
knowledge of the peroxisomal b-oxidation system, however, the reported biochemical aberrations can no longer
be explained by a deficiency of this thiolase. In this study, we show that the true defect in this patient is at the
level of D-bifunctional protein (DBP). Immunoblot analysis revealed the absence of DBP in postmortem brain of
the patient, whereas THIO was normally present. In addition, we found that the patient had a homozygous deletion
of part of exon 3 and intron 3 of the DBP gene, resulting in skipping of exon 3 at the cDNA level. Our findings
imply that the group of single–peroxisomal b-oxidation–enzyme deficiencies is limited to straight-chain acyl-CoA
oxidase, DBP, and a-methylacyl-CoA racemase deficiency and that there is no longer evidence for the existence of
THIO deficiency as a distinct clinical entity.
In 1986, Goldfischer et al. described a patient with clin-
ical features similar to those of patients with Zellweger
syndrome (MIM 214100) (Goldfischer et al. 1986). In
contrast to patients with Zellweger syndrome who lack
functional peroxisomes, however, this patient had ap-
parently normal peroxisomes in liver and kidney. There
was an accumulation of very-long-chain fatty acids
(VLCFAs) in plasma and of 3a,7a,12a-trihydroxycho-
lestanoic acid (THCA) in duodenal aspirate of the pa-
tient (Goldfischer et al. 1986). Later studies, by Clayton
et al. (1990), showed that 3a,7a,12a,24-tetrahydroxy-
cholestanoic acid (varanic acid), an intermediate in the
formation of cholic acid from THCA, was present in
body fluids of the patient. Immunoblot experiments by
Schram et al. (1987) revealed the absence of 3-ketoacyl-
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CoA thiolase (THIO) in postmortem liver of the patient,
whereas normal levels were found for other peroxisomal
matrix enzymes (i.e., acyl-CoA oxidase, bifunctional
protein, and catalase). These results led to the conclusion
that the strongly reduced rate of peroxisomal b-oxida-
tion measured in liver of the patient and the accumu-
lation of VLCFAs and THCA in body fluids were caused
by a deficiency of THIO (MIM 261510). After the iden-
tification, in 1991, of the gene encoding human THIO,
molecular studies in this patient were performed, but no
large DNA rearrangements involving the thiolase gene
were observed in Southern blot experiments (Bout et al.
1991).
At the time when the patient was described, it was
believed that the peroxisomal b-oxidation system con-
sisted of only a single set of enzymes: an acyl-CoAoxidase
catalyzing the first step, a bifunctional protein catalyzing
the second and third step, and a thiolase responsible for
the last step of the b-oxidation process. During the past
few years, however, a number of studies have shed new
light on the enzymology of the peroxisomal b-oxidation
system (for recent reviews, see van Veldhoven et al. 2001;
Wanders et al. 2001a, 2001b). These studies have shown
that peroxisomes contain two sets of b-oxidation en-
1590 Am. J. Hum. Genet. 70:1589–1593, 2002
Figure 1 Schematic representation of fatty-acid b-oxidation ma-
chinery in human peroxisomes catalyzing the oxidation of very-long-
chain fatty acyl-CoAs (VLCFA-CoA) and branched-chain fatty acyl-
CoAs (i.e., pristanoyl-CoA and THC-CoA). Oxidation of VLCFA-CoAs
C24:0 and C26:0 involves SCOX, DBP, and both THIO and SCPx,
whereas oxidation of branched-chain fatty acyl-CoAs involves BCOX,
DBP, and SCPx (for a review, see Wanders et al. 2001a).
Figure 2 Immunoblot analysis in postmortem kidney and brain of a control subject (lanes C), a patient suffering from Zellweger syndrome
(lanes Z), and the index patient (lanes P). Antibodies were used against (A) peroxisomal THIO (Tager et al. 1985), (B) DBP (Jiang et al. 1996),
(C) LBP (Tager et al. 1985), (D) SCOX (Tager et al. 1985), and (E) SCPx (Ossendorp et al. 1996). In A, the arrowheads indicate the 44-kD
precursor form and the 41-kD mature form of THIO; in B, the arrowheads indicate the 79-kD full-length protein, the 45 kD enoyl-CoA
hydratase component of DBP, and the 35-kD 3-hydroxyacyl-CoA dehydrogenase component of DBP; in C, the arrowhead indicates the 79-kD
full-length LBP; in D, the arrowheads indicate the 70-, 50-, and 20-kD components of SCOX; and, in E, the arrowheads indicate the 58-kD
full-length protein and the 46-kD thiolase component of SCPx.
zymes, which differ in substrate specificity (fig. 1). In ad-
dition to the original acyl-CoA oxidase, which is now
called “straight-chain acyl-CoA oxidase” (SCOX), a sec-
ond oxidase, called “branched-chain acyl-CoA oxidase”
(BCOX), has been identified. SCOX is responsible for the
oxidation of VLCFAs such as C26:0 and C24:0, whereas
BCOX is involved in the b-oxidation of pristanic acid and
of the bile-acid intermediates THCA and dihydroxycho-
lestanoic acid (DHCA) (fig. 1). The second bifunctional
protein that has been identified has been named “D-bi-
functional protein” (DBP), because it forms and dehy-
drogenates D-3-hydroxyacyl-CoAs, in contrast to theorig-
inal protein, L-bifunctional protein (LBP),which produces
L-hydroxy intermediates. Both in vitro studies performed
with the purified bifunctional proteins and the identifi-
cation of patients with a deficiency of DBP (MIM 261515
and 601860) (Suzuki et al. 1997; van Grunsven et al.
1998, 1999a, 1999b) have provided unequivocal evidence
that DBP is involved in the degradation of VLCFAs, as
well as of the branched-chain fatty acids, pristanic acid,
and DHCA/THCA. At present, the physiological function
of LBP remains elusive. Both peroxisomal thiolases are
believed to be involved in the degradation of VLCFAs. In
addition, sterol carrier protein X (SCPx), the second per-
oxisomal thiolase that has been identified, which contains
both a thiolase domain and a sterol carrier–protein do-
main, is the key enzyme in the b-oxidation of pristanic
acid and DHCA/THCA.
Since the new insights into the peroxisomal b-oxi-
dation system and into the physiological function of the
different b-oxidation enzymes no longer provide an ex-
planation for the biochemical findings in the reported
patient, we reinvestigated this unique case. In the orig-
inal report, it was concluded that there was a deficiency
of peroxisomal THIO in the index patient, because im-
munoblot experiments revealed the normal presence of
SCOX and LBP, but no THIO, in postmortem liver ma-
terial (Schram et al. 1987). To determine whether this
thiolase deficiency is caused by mutations in the gene
encoding THIO, we sequenced the cDNA, amplified by
RT-PCR, from RNA isolated from postmortem brain
and kidney material from the patient and from a control
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Figure 3 A, Schematic representation of exons 2–4 of D-bifunc-
tional protein (DBP) and the intervening intron sequences. The deletion
in the DBP gene in the index patient is indicated (from bp 145 in exon
3 through the first 63 bp of intron 3). This was determined by ampli-
fication of part of the DBP gene by primers –21MDBPIVS255F and
M13DBPIVS3E4, which are depicted, and subsequent sequencing of
the PCR products. On the genomic level, the deletion results in skipping
of exon 3, at the cDNA level. B, Products of amplification of the DBP
gene by primers –21MDBPIVS255F and M13DBPIVS3E4, in brain
of a control subject (lane C), the patient’s father (lane F), the patient’s
mother (lane M), and the index patient (lane P).
Table 1
Activity Measurements of the Enoyl-CoA Hydratase and 3-hydroxyacyl-CoA Dehydrogenase
Component of D-Bifunctional Protein, in Fibroblasts of the Patient’s Parents and in Control Subjects
ACTIVITY
MEASUREMENT IN
(pmol/min/mg)
Patient’s
Mother
Patient’s
Father Controls ( )anp 24
Hydratase (formation of 24-OH-THC-CoA) 86 127 240  65
Dehydrogenase (formation of 24-keto-THC-CoA) 10 26 73  33
a Values are mean  SD.
subject, in two overlapping fragments, by use of primers
THIOF-58 (5′-TGT TAA CTC CGC GGT CAG TTC
CCG GAC TGG-3′), THIOR 484 (5′-CCA GGG TTC
CCT CTG TCA GCC AGG GAC ATG-3′), THIOF 403
(5′-GTG GCA TCA GAA ATG GGT CTT ATG ACA
TTG-3′), and THIOR 1326 (5′-GCT GCT AGA GCA
GCA GGA CTG TCT GCG TAG-3′). Unfortunately, no
liver material from the patient could be used for this
study, because the liver samples used for the studies de-
scribed by Schram et al. (1987) were no longer available.
No mutations were identified by sequence analysis of
the cDNA encoding the thiolase from both brain and
kidney in the patient.
The absence of mutations in the cDNA encoding the
thiolase, in conjunction with the current view that per-
oxisomes contain two sets of b-oxidation enzymes,
prompted us to reinvestigate the patient, at the bio-
chemical level. To this end, we performed immunoblot
experiments using antibodies against the different en-
zymes, except BCOX, since no antibody against this en-
zyme was available. The results are shown in figure 2.
In contrast to the previous data for liver, the mature 41-
kD form of THIO was normally present in both brain
and kidney from the index patient (fig. 2A). Also, the
other peroxisomal thiolase, SCPx, as well as the 70-,
50-, and 20-kD components of SCOX and LBP were
normally present. DBP, however, was deficient in brain
from the index patient, whereas it was normally present
in brain of the control subject. The full-length protein,
79 kD, was not detectable; nor were the two proteolyt-
ically processed polypeptides: the 45-kD band corre-
sponding to the enoyl-CoA hydratase component of DBP
and the 35-kD band corresponding to the 3-hydroxy-
acyl-CoA dehydrogenase component of DBP. In kidney,
no DBP could be detected in either the control subject
or the index patient (fig. 2B).
Since no skin fibroblasts from the index patient were
available, we measured DBP activity (as described in the
report by van Grunsven et al. [1998]) in fibroblasts of
the patient’s parents and found partially reduced activity
(table 1), which is in agreement with heterozygosity for
DBP deficiency. To confirm the apparent DBP deficiency
in the index patient at the molecular level, we amplified
the cDNA encoding DBP, from brain and kidney, by
PCR, in three overlapping fragments, as described by
van Grunsven et al. (1998), and subsequently sequenced
the PCR products. We found a homozygous deletion of
bp 113–220, corresponding to exon 3 of the DBP gene
(Leenders et al. 1998). We also analyzed the cDNA en-
coding DBP in fibroblasts of the patient’s mother and
found a heterozygous deletion of exon 3. To determine
the cause of skipping of exon 3 in the patient, the 3′ end
of intron 2, exon 3, and intron 3 of the DBP gene were
amplified from brain and kidney DNA, by use of primers
–21MDBPIVS255F (5′-CAC ATT TTG AAA GTC
TAG AA-3′) and M13DBPIVS3E4 (5′-CAC CTA TTC
TTC CAA AAG CAT CC-3′), and the PCR products
were sequenced. This revealed a deletion of 138 bp, en-
compassing bp 145–220 of exon 3 and the first 63 bp
of intron 3 (fig. 3). In fibroblasts from the parents of the
patient, the same deletion was identified, in heterozygous
form.
The data presented in this study show that the true
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defect in the only patient documented with a deficiency
of THIO is at the level of DBP. No DBP protein could
be detected by immunoblot analysis in brain of the pa-
tient, whereas THIOwas normally present. These results
were confirmed by cDNA analysis in brain and kidney.
The cDNA encoding THIO was completely normal,
whereas the patient had a homozygous deletion of exon
3 in DBP cDNA. Studies at the genomic level revealed
that skipping of exon 3 in this patient is caused by a
deletion of part of exon 3 and the 5′ end of intron 3.
The parents of the patient, who were consanguineous,
are heterozygous for this deletion, which results in par-
tially reduced DBP activity, as measured in their fibro-
blasts. Exon 3 consists of 108 bp, and skipping of this
exon leads to an in-frame deletion of 36 amino acids.
Since neither the full-length, 79-kD band nor the 45-
and 35-kD bands, corresponding to the enoyl-CoA hy-
dratase and 3-hydroxyacyl-CoA dehydrogenase com-
ponents of DBP, respectively, were present in brain from
the patient, the mutated protein, if produced at all, is
probably unstable and rapidly degraded.
Our immunoblot experiments showed the normal
presence of THIO in kidney and brain from the index
patient, a finding that contrasts with the earlier data,
reported by Schram et al. (1987), showing the absence
of thiolase in liver. The most likely explanation for these
discrepant results is that the quality of the liver material
used by Schram et al. (1987), which was obtained post-
mortem, was very poor. Unfortunately, this possibility
cannot be investigated, since this liver material is no
longer available.
The first patient with a deficiency of DBP was de-
scribed in 1997, 10 years after the reported thiolase de-
ficiency in the index patient (Suzuki et al. 1997). Since
then, several other cases of DBP deficiency have been
reported in the literature (reviewed by Wanders et al.
[2001a]), and, to date, DBP deficiency constitutes one
of the most frequently occurring single-peroxisomal-
enzyme–deficiency disorders. The clinical as well as the
biochemical abnormalities in the index patient were sim-
ilar to those reported in patients with an establishedDBP
deficiency. The mutation identified in the patient has not
been reported before. Our findings have significant im-
plications, since they imply that the group of single–
peroxisomal b-oxidation–enzyme deficiencies is limited
to SCOX (Poll-The et al. 1988), DBP (Suzuki et al. 1997;
van Grunsven et al. 1998, 1999a, 1999b), and a-methyl-
acyl-CoA racemase deficiency (Ferdinandusse et al.
2000) and that THIO deficiency is no longer a distinct
disease entity. In conclusion, this study stresses the im-
portance, now that the knowledge of the peroxisomal
b-oxidation system and of the enzymes involved has im-
proved greatly during recent years, of reinvestigation of
patients who, in the literature, have been described as
having an unknown defect of peroxisomal b-oxidation.
The elucidation of the true defect in these patients will
further increase our understanding of the peroxisomal
b-oxidation system and its substrates and will be im-
portant for prenatal diagnosis in this group of patients.
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